Brief: Tetra Collaborates With Cellvera To Develop A Potential Oral Combination Treatment For Covid-19 Patients
06/09/2022 14:15
Sept 6 (Reuters) - Tetra Bio Pharma Inc TBP.TO :
* TETRA COLLABORATES WITH CELLVERA TO DEVELOP A POTENTIAL
ORAL
COMBINATION TREATMENT FOR COVID-19 PATIENTS
* TETRA BIO PHARMA INC - COMPANIES WILL JOINTLY DEVELOP A
COMBINATION THERAPEUTIC CANDIDATE FOR RAPID CLEARANCE OF
COVID-19 INFECTION
Source text for Eikon: ID:nCNW19JkSa
Further company coverage: TBP.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding